Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5941
    -0.0008 (-0.14%)
     
  • NZD/EUR

    0.5549
    +0.0009 (+0.16%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD

    2,349.60
    +7.10 (+0.30%)
     
  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    94.0360
    +1.5400 (+1.66%)
     

Estimates and Recommendations for Allergan in August

Estimates and Recommendations for Allergan in August

Analysts expect Allergan’s (AGN) adjusted EPS to be $16.29 on revenue of $15.53 billion in 2018, a 2.6% fall in revenue compared to $15.94 billion in 2017. Analysts expect the company’s adjusted net income to fall in 2018 mainly due to a fall in its gross profit margin and partially offset by a decrease in its selling, general, and administrative expenses as well as its research and development expenses. Allergan’s stock price has fallen nearly 20.2% over the last 12 months, but it’s risen ~12.8% year-to-date in 2018.